Clinical trial
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With…
NCT00238251 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00238251 |
|---|---|
| Title | Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases |
| Official title | Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Metastatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | gefitinib, temozolomide, radiation therapy |
| Enrollment | 59 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Nov 1, 2010 |
| First posted | Oct 13, 2005 |
| Last update posted | Jun 5, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: